



## Press Release

### Cellzome appoints David Simmons as Chief Scientific Officer

**Boston, 5th July 2006** - Cellzome Inc. is pleased to announce the appointment of David Simmons Ph.D. as Chief Scientific Officer.

For the past three years, David Simmons was Vice President, Inflammation Discovery Research at Wyeth Research in Boston, and co-chair of the Inflammation Therapeutic Area Leadership team ('TALT').

At Wyeth, David was responsible for the delivery of innovative pipeline projects and clinical development candidate drugs for inflammatory diseases. In addition, as a senior member of the Inflammation TALT, he had responsibility for disease area strategy, the delivery of the portfolio of anti-inflammatory drugs from Discovery through to Registration, and initiatives for research collaborations and in-licensing opportunities.

Before Wyeth, David was Director of Research at Celltech, Cambridge, responsible for the NCE drug discovery pipeline, including all medicinal chemistry on the Cambridge and Slough sites. Previously he had been Group Director, Neuroscience Research at SmithKline Beecham Pharmaceuticals.

From 1988 to 1997, he worked at the University of Oxford, starting as an independent post-doctoral research fellow and rising to become Wellcome Trust Senior Research Fellow at the Institute of Molecular Medicine, John Radcliffe Hospital. Before Oxford, David undertook research at the Department of Genetics, Harvard Medical School, and was a MRC post-doctoral research fellow at the University of Edinburgh.

David is currently a grant panel reviewer for the UK's Multiple Sclerosis Society and is a reviewer for the Wellcome Trust, Medical Research Council, Leukaemia Research Fund, Cancer Research Campaign and Arthritis Research Council.

Tim Edwards, CEO of Cellzome said: "On behalf of the Board, I am delighted to welcome David to Cellzome. He has recognized experience in drug discovery, translational medicine and early development. His knowledge will be of great value to Cellzome as we progress our current kinase projects and build our pipeline of small molecule therapeutics using the distinct advantages of our *Kinobeads* technology."

David Simmons added: "I am looking forward to joining Cellzome. I have been impressed with the team, the technology and the approach to discovering potent and selective kinase inhibitors to treat inflammatory diseases. This is an exciting area to be researching and a fertile ground for new therapies."

#### About Cellzome Inc.

Cellzome is a privately-owned drug discovery company applying its world-class proteomics technology to the discovery of novel small molecule therapeutics. Cellzome is commercializing its assets and technology by collaborating with major pharmaceutical companies and by developing its own pipeline of small molecule pharmaceuticals, initially for inflammatory disease.

Cellzome is working with Novartis Institutes for BioMedical Research Inc., ('NIBRI') in a large pan-therapeutic collaboration discovering new drug targets and leads in a variety of diseases. The Company is also collaborating with Ortho-McNeil Pharmaceutical and Johnson & Johnson PRD, focusing on developing a series of small-molecule gamma-secretase modulators for the treatment of Alzheimer's Disease.

In the development of its own pipeline, Cellzome is applying its proprietary *Kinobeads* technology to the discovery and development of novel, selective inflammatory kinase inhibitors targeting key inflammatory mediators in immune receptor signaling and chemotaxis.

Cellzome is intent on developing both organically and through merger or acquisition. Its holding company is domiciled in the USA and it employs about 80 people at its two operating subsidiaries in Cambridge, UK and Heidelberg, Germany. To learn more about Cellzome, please visit the website: [www.cellzome.com](http://www.cellzome.com)

#### For further information please contact:

**Cellzome AG**  
Tim Edwards  
Chief Executive Officer  
Tel: +49 (0) 6221-137 57-100  
[press@cellzome.com](mailto:press@cellzome.com)

**Media Contact**  
**Hogarth Partnership**  
John Olsen/Melanie Toyne-Sewell  
Tel: +44 (0) 207 357 9477  
[mtoyne-sewell@hogarthpr.co.uk](mailto:mtoyne-sewell@hogarthpr.co.uk)